AD
MCID: ALZ034
MIFTS: 87

Alzheimer Disease (AD)

Categories: Genetic diseases, Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Alzheimer Disease

MalaCards integrated aliases for Alzheimer Disease:

Name: Alzheimer Disease 57 12 24 53 25 75 29 6 44 38 40
Alzheimer's Disease 38 12 76 25 37 29 6 43 3 15 63 73
Ad 57 12 25 75
Presenile and Senile Dementia 57 25 75
Alzheimer Disease, Late-Onset, Susceptibility to 57 6
Alzheimer Disease, Susceptibility to 57 6
Alzheimer Disease 1, Familial 57 13
Familial Alzheimer Disease 25 73
Alzheimer Disease, Early-Onset, with Cerebral Amyloid Angiopathy 6
Early-Onset Alzheimer Disease with Cerebral Amyloid Angiopathy 75
Primary Senile Degenerative Dementia 25
Autosomal Dominant Alzheimer Disease 75
Dementia Due to Alzheimer's Disease 73
Alzheimer's Disease Pathway Kegg 73
Alzheimer Disease, Late-Onset 57
Alzheimer's Disease, Familial 76
Alzheimer Disease, Familial 12
Alzheimer Disease Type 1 73
Alzheimer-Type Dementia 25
Alzheimers Dementia 12
Alzheimer Disease 1 75
Alzheimer Sclerosis 25
Alzheimer Dementia 25
Alzheimer Syndrome 25
Alzheimers Disease 55
Sdat 25
Ad1 75
Dat 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
alzheimer disease:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Alzheimer Disease

NINDS : 54 Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. Initially, people experience memory loss and confusion, which may be mistaken for the kinds of memory changes that are sometimes associated with normal aging. However, the symptoms of AD gradually lead to behavior and personality changes, a decline in cognitive abilities such as decision-making and language skills, and problems recognizing family and friends. AD ultimately leads to a severe loss of mental function. These losses are related to the worsening breakdown of the connections between certain neurons in the brain and their eventual death. AD is one of a group of disorders called dementias that are characterized by cognitive and behavioral problems. It is the most common cause of dementia among people age 65 and older. There are three major hallmarks in the brain that are associated with the disease processes of AD. Amyloid plaques, which are made up of fragments of a protein called beta-amyloid peptide mixed with a collection of additional proteins, remnants of neurons, and bits and pieces of other nerve cells. Neurofibrillary tangles (NFTs), found inside neurons, are abnormal collections of a protein called tau. Normal tau is required for healthy neurons. However, in AD, tau clumps together. As a result, neurons fail to function normally and eventually die. Loss of connections between neurons responsible for memory and learning. Neurons can't survive when they lose their connections to other neurons. As neurons die throughout the brain, the affected regions begin to atrophy, or shrink. By the final stage of AD, damage is widespread and brain tissue has shrunk significantly.

MalaCards based summary : Alzheimer Disease, also known as alzheimer's disease, is related to alzheimer disease 2 and early-onset, autosomal dominant alzheimer disease, and has symptoms including angina pectoris, back pain and headache. An important gene associated with Alzheimer Disease is APP (Amyloid Beta Precursor Protein), and among its related pathways/superpathways are Alzheimer's disease and MicroRNAs in cancer. The drugs Galantamine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include Brain and Blood, and related phenotypes are dementia and parkinsonism

OMIM : 57 Alzheimer disease is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder characterized by the neuropathologic findings of intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques that accumulate in vulnerable brain regions (Sennvik et al., 2000). Terry and Davies (1980) pointed out that the 'presenile' form, with onset before age 65, is identical to the most common form of late-onset or 'senile' dementia, and suggested the term 'senile dementia of the Alzheimer type' (SDAT). Haines (1991) reviewed the genetics of AD. Selkoe (1996) reviewed the pathophysiology, chromosomal loci, and pathogenetic mechanisms of Alzheimer disease. Theuns and Van Broeckhoven (2000) reviewed the transcriptional regulation of the genes involved in Alzheimer disease. (104300)

UniProtKB/Swiss-Prot : 75 Alzheimer disease: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. Alzheimer disease 1: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

NIH Rare Diseases : 53 Alzheimer disease (AD) is a degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. Alzheimer disease currently affects about 5 million people. About 75 percent of Alzheimer disease cases are classified as sporadic, which means they occur in people with no history of the disorder in their family. Although the cause of these cases is unknown, genetic changes are likely to play a role. Virtually all sporadic cases of Alzheimer disease begin after age 65, and the risk of developing this condition increases as a person gets older. AD can be subdivided into two groups based on the age of onset: (1) Early-onset (1%-6% of the cases) which start in people younger than 60- 65 years of age (2) Late-onset, which starts in people older than 65 years old. In about 25% of cases, AD is familial (2 or more people in a family have AD). For more information, please visit GARD's familial Alzheimer disease Web page.

MedlinePlus : 43 Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD. In AD, over time, symptoms get worse. People may not recognize family members. They may have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them. AD usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease. No treatment can stop the disease. However, some drugs may help keep symptoms from getting worse for a limited time. NIH: National Institute on Aging

CDC : 3 The most common type of dementia. A progressive disease beginning with mild memory loss possibly leading to loss of the ability to carry on a conversation and respond to the environment. Involves parts of the brain that control thought, memory, and language. Can seriously affect a person’s ability to carry out daily activities.

Genetics Home Reference : 25 Alzheimer disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood.

Disease Ontology : 12 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

PubMed Health : 63 About alzheimer's disease: Alzheimer's disease is the most common cause of dementia. It takes its name from the psychiatrist Alois Alzheimer, who in the early twentieth century was the first person to describe the disease. Over time, people who have Alzheimer’s lose their memory and ability to concentrate. Orientation in space and time become increasingly difficult, and it is also harder for them to manage on their own in everyday life. Those affected need more support as the disease progresses.The course of Alzheimer’s can be positively influenced by a number of different medications and non-drug treatments – but it is not possible to cure the disease or to keep it from progressing. This makes it even more critical for people with Alzheimer’s to receive good care and support: They need loving and stable relationships and a tolerant environment. Many family members need help and assistance too.There are other possible causes of dementia besides Alzheimer’s disease. These include problems with the flow of blood in the brain (vascular dementia). Some people – particularly older people – have both Alzheimer’s and vascular dementia. Medical conditions such as Parkinson’s disease, brain injuries or tumors can also cause dementia. Long-term heavy alcohol consumption may lead to dementia too.There are similarities, but also differences, between the different forms of dementia: The symptoms, the course the disease takes, and the treatment options can all vary. This overview is only about Alzheimer’s.

Wikipedia : 76 Alzheimer\'s disease (AD), also referred to simply as Alzheimer\'s, is a chronic neurodegenerative... more...

GeneReviews: NBK1161

Related Diseases for Alzheimer Disease

Diseases in the Alzheimer Disease family:

Alzheimer Disease 2 Alzheimer Disease 16
Alzheimer Disease 5 Alzheimer Disease 6
Alzheimer Disease 7 Alzheimer Disease 4
Alzheimer Disease 8 Alzheimer Disease 3
Alzheimer Disease 9 Alzheimer Disease 10
Alzheimer Disease 11 Alzheimer Disease 12
Alzheimer Disease 13 Alzheimer Disease 14
Alzheimer Disease 15 Alzheimer Disease 17
Alzheimer Disease 18 Alzheimer Disease 19
Early-Onset Familial Alzheimer Disease Alzheimer Disease Type 1
Early-Onset, Autosomal Dominant Alzheimer Disease

Diseases related to Alzheimer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 2 36.1 APP NOS3 PLAU
2 early-onset, autosomal dominant alzheimer disease 35.8 APP SORL1
3 inclusion body myositis 31.6 APP BACE1 BACE1-AS MIR34A
4 diabetes mellitus 31.4 CDKN2B-AS1 HFE MIR34A MT-ND1 NOS3
5 alzheimer disease 19 12.4
6 alzheimer disease 3 12.4
7 alzheimer disease 6 12.3
8 alzheimer disease 4 12.3
9 alzheimer disease 18 12.3
10 alzheimer disease 9 12.3
11 alzheimer disease mitochondrial 12.2
12 alzheimer disease 5 12.2
13 alzheimer disease 7 12.2
14 alzheimer disease 8 12.2
15 alzheimer disease 12 12.2
16 alzheimer disease 10 12.1
17 alzheimer disease 11 12.1
18 alzheimer disease 15 12.1
19 early-onset familial alzheimer disease 12.1
20 alzheimer disease 13 12.1
21 alzheimer disease 14 12.1
22 alzheimer disease 17 12.0
23 alzheimer disease type 1 12.0
24 alzheimer disease 16 11.9
25 dopa-responsive dystonia; segawa syndrome ad 11.9
26 alzheimer disease without neurofibrillary tangles 11.9
27 alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology 11.9
28 hyper-ige recurrent infection syndrome, autosomal dominant 11.7
29 dementia, lewy body 11.7
30 immunodeficiency 27b 11.6
31 myopathy, centronuclear, 1 11.5
32 renal tubular acidosis, distal, autosomal dominant 11.5
33 hypocalcemia, autosomal dominant 1 11.4
34 arteritic anterior ischemic optic neuropathy 11.3 MPO MT-ND1 NOS3
35 supranuclear palsy, progressive, 1 11.2
36 posterior cortical atrophy 11.2
37 parkinson disease, late-onset 11.2
38 down syndrome 11.1
39 schizophrenia 11.1
40 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.1
41 cerebral amyloid angiopathy, app-related 11.1
42 buerger disease 11.0 NOS3 PLAU
43 slc6a3-related dopamine transporter deficiency syndrome 10.9
44 ovarian cancer 10.9 BACE1-AS CDKN2B-AS1 MIR106B MIR146A MIR29A PLAU
45 oral squamous cell carcinoma 10.8 MIR146A MIR29A MIR34A
46 leukemia, acute myeloid 10.8 CDKN2B-AS1 MIR146A MIR328 MPO
47 parkinson disease 1, autosomal dominant 10.7
48 frontotemporal dementia, chromosome 3-linked 10.7
49 thyroid cancer, nonmedullary, 1 10.7 MIR146A MIR29A MIR34A
50 dementia 10.6

Comorbidity relations with Alzheimer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Amnestic Disorder Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dental Caries
Dermatomycosis Encephalopathy
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Atherosclerosis Grn-Related Frontotemporal Dementia
Heart Disease Hypoglycemia
Hypothyroidism Intermittent Explosive Disorder
Intestinal Volvulus Iron Deficiency Anemia
Kidney Disease Kohlschutter-Tonz Syndrome
Latent Syphilis Major Depressive Disorder
Marasmus Neurogenic Bladder
Nutritional Deficiency Disease Obstructive Hydrocephalus
Ocular Motor Apraxia Oral Candidiasis
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Pernicious Anemia Personality Disorder
Protein-Energy Malnutrition Pyelonephritis
Scabies Schizophrenia

Graphical network of the top 20 diseases related to Alzheimer Disease:



Diseases related to Alzheimer Disease

Symptoms & Phenotypes for Alzheimer Disease

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
parkinsonism
presenile and senile dementia
long tract signs
neurofibrillary tangles composed of disordered microtubules


Clinical features from OMIM:

104300

Human phenotypes related to Alzheimer Disease:

32 (show all 7)
# Description HPO Frequency HPO Source Accession
1 dementia 32 HP:0000726
2 parkinsonism 32 HP:0001300
3 neurofibrillary tangles 32 HP:0002185
4 senile plaques 32 HP:0100256
5 alzheimer disease 32 HP:0002511
6 long-tract signs 32 HP:0002423
7 decreased level of gaba in serum 32 HP:0410054

UMLS symptoms related to Alzheimer Disease:


angina pectoris, back pain, headache, myoclonus, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Alzheimer Disease

PubMedHealth treatment related to Alzheimer Disease: 63

People who have Alzheimer’s need long-term help and treatment. Depending on their needs, their life situation and the stage of disease, a whole team of people may be involved in providing care. These could include trained doctors, psychologists, nurses and social workers, as well as volunteers. Both treatment with medications and non-drug interventions aim toincrease quality of life,keep the ability to do everyday tasks and stay independent for as long as possible,reduce mental health problems, andhelp family members to cope better.The most common medications used to treat Alzheimer’s disease include cholinesterase inhibitors, memantine and extracts from the leaves of the Ginkgo biloba tree.Examples of non-drug treatments include memory and orientation training, doing everyday activities as a group, or art therapy, aromatherapy, and animal-assisted or music therapy. Physical activities and massages can help too. Caregiver training for family members is important too.

Drugs for Alzheimer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 670)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 357-70-0 9651
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
3
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19982-08-2 4054
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
7
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
8
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
9
Levodopa Approved Phase 4,Phase 1,Phase 2,Not Applicable 59-92-7 6047
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 50-78-2 2244
11
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
12
Rivaroxaban Approved Phase 4 366789-02-8
13
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
14
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 6691 54678486
15
Huperzine A Approved, Investigational Phase 4,Phase 2,Phase 3 102518-79-6
16
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
17
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
18
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
19 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
20
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
21
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
22
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
23
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
24
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113-45-1 4158
25
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
26
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
27
Isoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 26675-46-7 3763
28
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
29
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
30
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
31
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
32
Cilostazol Approved, Investigational Phase 4,Phase 2 73963-72-1 2754
33
Ramipril Approved Phase 4 87333-19-5 5362129
34
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
35
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
36
Pravastatin Approved Phase 4 81093-37-0 54687
37
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
38
Norepinephrine Approved Phase 4,Phase 1,Not Applicable 51-41-2 439260
39
Olanzapine Approved, Investigational Phase 4,Not Applicable 132539-06-1 4585
40
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
41
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
43
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
46
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
47 Piracetam Approved, Investigational Phase 4,Phase 2,Not Applicable 7491-74-9
48
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
49
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
50
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776

Interventional clinical trials:

(show top 50) (show all 2420)
# Name Status NCT ID Phase Drugs
1 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
4 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
6 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
7 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
8 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
9 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
10 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
11 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
12 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
13 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
14 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4 cognitive function
15 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4 Memantine;Placebo
16 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
17 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
18 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
19 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4 Rivastigmine transdermal patch
20 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed NCT01948791 Phase 4 ENA713
21 NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. Completed NCT02703636 Phase 4 Rivastigmine Patch
22 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4 Carvedilol;Placebo
23 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
24 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed NCT02097056 Phase 4 Donepezil HCL
25 Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Completed NCT00731224 Phase 4 Rivastigmine transdermal patch
26 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease Completed NCT01054976 Phase 4 Galantamine
27 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
28 Escitalopram for the Treatment of Depression in Alzheimer's Disease Completed NCT01841125 Phase 4 escitalopram;Placebo
29 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NCT00120874 Phase 4 Memantine
30 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed NCT00476008 Phase 4 Memantine;Placebo
31 Double Blind Study of Trp01 in Patients With Alzheimer's Disease Completed NCT00202124 Phase 4 Tryptophan
32 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed NCT00561392 Phase 4 Rivastigmine 5 and 10 cm^2 patch
33 Neural Correlates In Mild Alzheimer's Disease Completed NCT00477659 Phase 4 donepezil HCl (Aricept)
34 A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease Completed NCT01047579 Phase 4 Rivastigmine transdermal
35 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4 memantine
36 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease Completed NCT00035204 Phase 4 galantamine
37 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo
38 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed NCT00622713 Phase 4 Rivastigmine transdermal patch
39 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
40 Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) Completed NCT00867828 Phase 4
41 EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) Completed NCT00230568 Phase 4 Aricept
42 A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease Completed NCT01122329 Phase 4
43 The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4 Galantamine CR;Memantine;Placebo
44 Memantine for Agitation and Aggression in Severe Alzheimer's Disease Completed NCT00401167 Phase 4 memantine
45 The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility Completed NCT00571064 Phase 4 Donepezil HCl
46 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease Completed NCT00933608 Phase 4 memantine;Placebo
47 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed NCT01585272 Phase 4 ENA713
48 Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil Completed NCT01478633 Phase 4 Galantamine
49 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4 memantine HCl
50 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo

Search NIH Clinical Center for Alzheimer Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alzheimer Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alzheimer Disease:
NEUROSTEM
Embryonic/Adult Cultured Cells Related to Alzheimer Disease:
Umbilical cord blood-derived mesenchymal stem/progenitor cells PMIDs: 23293711 22015609

Cochrane evidence based reviews: alzheimer disease

Genetic Tests for Alzheimer Disease

Genetic tests related to Alzheimer Disease:

# Genetic test Affiliating Genes
1 Alzheimer's Disease 29 A2M ACE APBB2 APP BLMH HFE MPO NOS3 PAXIP1 PLAU SORL1
2 Alzheimer Disease 29

Anatomical Context for Alzheimer Disease

MalaCards organs/tissues related to Alzheimer Disease:

41
Brain, Testes, Cortex, Temporal Lobe, Endothelial, Eye, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alzheimer Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate, affected by disease
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
3 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate, affected by disease
5 Brain Hippocampus Affected by disease

Publications for Alzheimer Disease

Articles related to Alzheimer Disease:

(show top 50) (show all 13304)
# Title Authors Year
1
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease. ( 29441654 )
2018
2
Structural heterogeneity and intersubject variability of AI^ in familial and sporadic Alzheimer's disease. ( 29311311 )
2018
3
Alzheimer Disease Clinical Trial Recruitment: Does Participation in a Brief Cognitive Screen at a Community Health Fair Promote Research Engagement? ( 29944475 )
2018
4
Correction to: Comparison of the Effect of Exercise on Late-Phase LTP of the Dentate Gyrus and CA1 of Alzheimer's Disease Model. ( 28983832 )
2018
5
Strategic value-directed learning and memory in Alzheimer's disease and behavioural-variant frontotemporal dementia. ( 29431279 )
2018
6
Noncoding RNAs in Alzheimer's disease. ( 29327503 )
2018
7
The "glymphatic" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? ( 29101220 )
2018
8
Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. ( 28943286 )
2018
9
Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer's disease. ( 29097221 )
2018
10
Causal association between rheumatoid arthritis and aA decreased risk of Alzheimer's disease : AA Mendelian randomization study. ( 29974225 )
2018
11
Visual texture agnosia in dementia with Lewy bodies and Alzheimer's disease. ( 29673784 )
2018
12
Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings. ( 28876969 )
2018
13
Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. ( 29254094 )
2018
14
Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. ( 29170097 )
2018
15
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018
16
Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study. ( 29282328 )
2018
17
Usability study and pilot validation of a computer-based emotion recognition test for older adults with Alzheimer's disease and amnestic mild cognitive impairment. ( 29356568 )
2018
18
Alzheimer's disease and primary open-angle glaucoma associated with vascular health in patients of African descent. ( 29855159 )
2018
19
Toward a Rational Design to Regulate I^-Amyloid Fibrillation for Alzheimer's Disease Treatment. ( 29251488 )
2018
20
Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. ( 29412849 )
2018
21
Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease. ( 29278888 )
2018
22
Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort. ( 29387418 )
2018
23
Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease. ( 29226874 )
2018
24
New Perspectives of Alzheimer Disease Diagnosis - the Most Popular and Future Methods. ( 28969570 )
2018
25
Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. ( 29125485 )
2018
26
Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau but Not with Amyloid Pathology: An Immunohistochemical Study. ( 29402847 )
2018
27
[Anesthesia and Alzheimer disease - Current perceptions]. ( 29137871 )
2018
28
Optimization of DARTEL Settings for the Detection of Alzheimer Disease. ( 29419401 )
2018
29
Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. ( 29944474 )
2018
30
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. ( 29438037 )
2018
31
Exercise Training on Locomotion in Patients with Alzheimer's Disease: A Feasibility Study. ( 29376858 )
2018
32
The Broken Lens of BPSD: Why We Need to Rethink the Way We Label the Behavior of People Who Live With Alzheimer Disease. ( 29413393 )
2018
33
Alzheimer disease biomarkers and synucleinopathy. ( 29467302 )
2018
34
Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. ( 29254091 )
2018
35
Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study. ( 29929471 )
2018
36
Reply: Cerebrospinal Fluid, Hyposmia and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. ( 29439014 )
2018
37
Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. ( 29131306 )
2018
38
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. ( 29063518 )
2018
39
Alzheimer's disease. ( 28872215 )
2018
40
Alzheimer's Disease: From Firing Instability to Homeostasis Network Collapse. ( 29301104 )
2018
41
Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model. ( 29376847 )
2018
42
Navigational cue effects in Alzheimer's disease and posterior cortical atrophy. ( 29928653 )
2018
43
Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease. ( 29924942 )
2018
44
Distinct Patterns of Rich Club Organization in Alzheimer's Disease and Subcortical Vascular Dementia: A White Matter Network Study. ( 29710719 )
2018
45
REM Sleep Behavior Disorder and Alzheimer's Disease: Definitely No Relationship? ( 29578489 )
2018
46
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. ( 29307736 )
2018
47
[Map of Alzheimer's disease and other dementias in Spain. MapEA Project]. ( 29107401 )
2018
48
High fat diet treatment impairs hippocampal long-term potentiation without alterations of the core neuropathological features of Alzheimer disease. ( 29427755 )
2018
49
Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: Small Windows, Big Picture. ( 29435570 )
2018
50
Cerebrospinal fluid CD4+ T lymphocyte-derived miRNA-let-7b can enhances the diagnostic performance of Alzheimer's disease biomarkers. ( 29170128 )
2018